Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,493 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Completed Phase 2 Interventional Results available

Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg

NCT00589121
View directory record Official record
Conditions
Lymphedema, Musculoskeletal Complications, Radiation Fibrosis, Radiation Toxicity, Sarcoma
Interventions
Chemotherapy, Radiation therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
14
States / cities
Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 9:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

NCT03539731
View directory record Official record
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 23, 2026, 9:32 PM EDT
Enrolling by invitation Not applicable Interventional

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT07499128
View directory record Official record
Conditions
Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions
TempTraq, VitalTraq
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1

NCT00158171
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
Nicotine Replacement Therapies, Nicotine patch, Folic Acid
Drug · Dietary Supplement
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
13 Years to 18 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test

NCT02750475
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Sport Lotion (BAY987516), Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 23, 2026, 9:32 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

NCT06962904
View directory record Official record
Conditions
Rotavirus Infections
Interventions
3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo
Biological · Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Body Temperature in Persons With Tetraplegia When Exposed to Cold

NCT01822535
View directory record Official record
Conditions
Tetraplegia, Hypothermia, Mild Cognitive Impairment
Interventions
Midodrine hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 68 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

NCT02256540
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Climara, Placebo patch, Resveratrol, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 23, 2026, 9:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects

NCT07794150
View directory record Official record
Conditions
Menopause, Healthy Female Participants
Interventions
Estradiol/Levonorgestrel Transdermal System
Drug
Lead sponsor
Corium Innovations, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

The SOS (Stenting Of Saphenous Vein Grafts) Trial

NCT00247208
View directory record Official record
Conditions
Coronary Artery Bypass, Arteriosclerosis
Interventions
Taxus polymer-based paclitaxel-eluting stent, Express 2 bare metal stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Little Rock, Arkansas • Iowa City, Iowa • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 23, 2026, 9:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Assessment of a Teachable Moment for Smoking Cessation

NCT00596440
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transdermal nicotine patch
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 23, 2026, 9:32 PM EDT
Withdrawn Not applicable Interventional

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

NCT02183896
View directory record Official record
Conditions
Femoroacetabular Impingement, Chondral Lesions
Interventions
Platelet-rich plasma (PRP), Saline
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 23, 2026, 9:32 PM EDT
Active, not recruiting Phase 1 Interventional

Focused Ultrasound and Gemcitabine in Breast Cancer

NCT04796220
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Focused Ultrasound, Gemcitabine and Focused Ultrasound
Device · Other
Lead sponsor
Patrick Dillon, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 9:32 PM EDT
Active, not recruiting Phase 1 Interventional

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579
View directory record Official record
Conditions
Breast Cancer
Interventions
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

NCT02395042
View directory record Official record
Conditions
Cystitis, Interstitial, Ulcer
Interventions
LiRIS®, LiRIS Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Murrieta, California • Vacaville, California • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

NCT01757717
View directory record Official record
Conditions
Metastatic or Recurrent Lesions in the Spine, Metastatic or Recurrent Lesions in the Pelvis
Interventions
Ir-192 high dose rate (HDR)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 23, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

A Superiority Trial of Radiofrequency Ablation for Low Back Pain

NCT07222462
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP)
Interventions
Lumbar radiofrequency ablation with conventional electrodes (LRFA-C), Lumbar radiofrequency ablation with multi-tined electrodes (LRFA-M), Simulated lumbar radiofrequency ablation
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia • Cleveland, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

NCT00269620
View directory record Official record
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 23, 2026, 9:32 PM EDT
Recruiting Phase 2 Interventional

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 9:32 PM EDT